Pharmacology/Pharmaceutical Industry | Page 48 of 172 | Links Medicus Content Curation & Alerts in Medicine

🆕 WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. pic.twitter.com/dp2A1knGtT

— World Health Organization (WHO) (@WHO) November 3, 2021

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

4 Nov, 2021 | 10:06h | UTC

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Commentaries:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

ASH Guideline issued a conditional recommendation against routine use of outpatient anticoagulant prophylaxis in patients with COVID-19 being discharged from the hospital.

4 Nov, 2021 | 10:03h | UTC

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis – Blood Advances

M-A: Zinc might help to stave off respiratory infection symptoms and cut illness duration – “But quality of evidence variable, and no clarity on optimal formulation or dose”.

4 Nov, 2021 | 09:53h | UTC

News Release: Zinc might help to stave off respiratory infection symptoms and cut illness duration – BMJ

Original Study: Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials – BMJ Open

Commentary on Twitter

A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence, published in @BMJ_Open https://t.co/Nq5KadAw5y

— BMJ Group (@bmj_company) November 2, 2021

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

4 Nov, 2021 | 09:58h | UTC

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

Commentary on Twitter

NEW—Cervical cancer rates 87% lower in women offered vaccination against human papillomavirus (#HPV) between ages 12-13 than in previous generations, English study confirms.

First direct evidence of cervical cancer prevention using bivalent vaccine: https://t.co/HdQbGIKxZp pic.twitter.com/PMFermHGOv

— The Lancet (@TheLancet) November 3, 2021

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

3 Nov, 2021 | 10:09h | UTC

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm – The Lancet Infectious Diseases

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

3 Nov, 2021 | 10:11h | UTC

ACIP Presentation Slides: November 2-3, 2021 Meeting – Centers for Disease Control and Prevention

Commentaries:

CDC advisors give go-ahead to COVID-19 vaccines for young kids – CIDRAP

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11 – STAT

American Academy of Pediatrics Applauds CDC Advisory Committee’s Approval of Safe, Effective COVID-19 Vaccine for Children Ages 5-11

RCT: Among children with community-acquired pneumonia discharged within 48 hours from the ED or hospital, lower-dose outpatient oral amoxicillin was noninferior to a higher dose, and a 3-day duration course was noninferior to 7 days.

3 Nov, 2021 | 09:56h | UTC

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA (free for a limited period)

RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia

Randomized Trial: Amoxicillin for 3 Days Noninferior to Amoxicillin for 5 Days for Chest-Indrawing Pneumonia in Children

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.

RCT: A Seven-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales was noninferior to a 14-days course.

RCT: Among patients with prosthetic joint infection, antibiotic therapy for 6 weeks was NOT shown to be noninferior to antibiotic therapy for 12 weeks and resulted in a higher percentage of patients with unfavorable outcomes.

Randomized Trial: Seven vs. Fourteen Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia

Commentary on Twitter

🔥Just published🔥
CAP-IT RCT
Children w CAP discharged from ED or hospital (w/in48 hrs)
lower-dose outpatient oral amoxicillin was noninferior to higher dose& 3d was noninferior to 7 d, w regard to need for Abx re-treatment @BradSpellberg table update 🤔 https://t.co/VkxBmJaEeW pic.twitter.com/fKzpGp1XM7

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) November 2, 2021

AAP Policy Statement: Preventing Home Medication Administration Errors.

3 Nov, 2021 | 09:58h | UTC

Preventing Home Medication Administration Errors – Pediatrics

Commentary: Ways to Prevent Children’s Medication Errors at Home – American Academy of Pediatrics

Commentary on Twitter

This policy statement recommends strategies to reduce the incidence of pediatric medication administration errors at home, including those involving prescription and over-the-counter medications, as well as vitamins/supplements: https://t.co/vgqGNqw5NJ #Pediatrics pic.twitter.com/ar4EeZSxs0

— AAP CME Journals (@AAPJournals) November 2, 2021

J&J Covid-19 vaccination is associated with increased risk of cerebral venous sinus thrombosis.

2 Nov, 2021 | 03:02h | UTC

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination – JAMA

Commentary: Cerebral Venous Sinus Thrombosis Rate Up After Ad26.COV2.S Shot – HealthDay

Study shows increased risk of Guillain-Barré syndrome following vaccination with recombinant zoster vaccine – “an attributable risk of 3 cases per million RZV (Shingrix) doses”.

2 Nov, 2021 | 02:45h | UTC

Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries – JAMA Internal Medicine (free for a limited period)

Consensus Statement: Preoperative management of gastrointestinal and pulmonary medications.

2 Nov, 2021 | 02:53h | UTC

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Related articles from Mayo Clinic Proceedings:

Consensus Statement: Preoperative management of endocrine, hormonal, and urologic medications

Consensus statement: Preoperative management of opioid and nonopioid analgesics

Perioperative evaluation and management of patients with diabetes, thyroid disease, and adrenal insufficiency. Use of insulin and noninsulin diabetic medications, management of hyper and hypothyroidism, and use of stress-dose corticosteroids are some of the subjects reviewed

Review: Preoperative Cardiac Risk Assessment

Review | Perioperative cardiac risk reduction in noncardiac surgery.

Systematic Review of Perioperative Cardiac Risk Prediction Indices

Review: Perioperative venous thromboembolism prophylaxis

Short Review: Metronidazole-induced neurotoxicity.

2 Nov, 2021 | 02:41h | UTC

Metronidazole-induced neurotoxicity – Canadian medical Association Journal

Commentary on Twitter

The ability of metronidazole to cause neurotoxicity is not widely appreciated. Here's our quick overview led by @DanicaQuickfall, just out in @CMAJ.
https://t.co/7sggYzCzGN pic.twitter.com/miW0trFuYv

— David Juurlink (@DavidJuurlink) October 25, 2021

Short Review: Ketamine for the treatment of acute pain.

2 Nov, 2021 | 02:43h | UTC

Ketamine for the treatment of acute pain – Canadian Medical Association Journal

Commentary on Twitter

If you manage pain in hospital, low-dose ketamine should be in your toolkit. And not just in the ED.

Quick overview with @WKSilverstein & @JonZipursky in @CMAJ: https://t.co/w5h3vIMiEK pic.twitter.com/gVO7W9dcYY

— David Juurlink (@DavidJuurlink) November 1, 2021

Observational study suggests a third dose of the Pfizer COVID-19 vaccine can prevent severe COVID-19-related outcomes, compared with only two doses received at least 5 months before.

31 Oct, 2021 | 20:14h | UTC

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study – The Lancet

Invited Commentary: Boosters appear effective, but are they always needed? – The Lancet

Commentaries on Twitter

Nice analysis of boosters in @TheLancet Fri.: https://t.co/KqXInFa3a9

But I want to highlight one number:

Risk of severe disease w no booster & no coexisting conditions = 1 in 32,000 (3 per 100k).

If you have no other medical problems, this is not an urgent priority. pic.twitter.com/Qwcwsf6LIY

— David Dowdy (@davidwdowdy) October 31, 2021

Study in Israel suggests third dose of BNT162b2 mRNA vaccine effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months before. https://t.co/g3vFqVFZLI pic.twitter.com/HfbBAPY8qP

— The Lancet (@TheLancet) October 31, 2021

Adding to the body of data for booster shot effectiveness, a new @TheLancet report of over 728,000 people w/ 3 shots vs >728,000 matched controls (2 shots):
93% reduction of Covid hospitalizationshttps://t.co/cVpANpnkHs pic.twitter.com/LlBwWi2Vtw

— Eric Topol (@EricTopol) October 30, 2021

Editorial: Safety and efficacy of antivirals against SARS-CoV-2 – “we need evidence not optimism”.

31 Oct, 2021 | 20:11h | UTC

Safety and efficacy of antivirals against SARS-CoV-2 – The BMJ

Commentary on Twitter

"Effective antivirals have an obvious appeal, but this must not cloud objective and transparent decision making." @dpsg108 and colleagues on the government's stockpiling of molnupiravir and PF-07321332+ritonavir for covid-19https://t.co/JUj1Y9op3P

— The BMJ (@bmj_latest) October 28, 2021

CDC Study: COVID-19 vaccine associated with 5 times the protection of ‘natural immunity’.

31 Oct, 2021 | 20:09h | UTC

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

COVID-19 vaccine gives 5 times the protection of ‘natural immunity,’ data show – CIDRAP

COVID shots more protective than past infection, study shows – Associated Press

Commentary on Twitter

⚠️BREAKING—REINFECTION & NATURAL IMMUNITY—new CDC study in hospitalized adults finds: unvaccinated people with prior #COVID19 infection recently were **5 times more likely** to be reinfected / get breakthrough versus people recently fully vaccinated! 🧵 https://t.co/VGmWPmm5lE pic.twitter.com/mlt5fJ3643

— Eric Feigl-Ding (@DrEricDing) October 29, 2021

Opinion | Is Moderna really better than Pfizer—or is it just a higher dose?

31 Oct, 2021 | 20:06h | UTC

Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose? – The Atlantic

Commentary on Twitter

Nice piece @theatlantic explores question of: Does Moderna give better protection than Pfizer, which gives better protection than J&J (the data would say yes to both)? And – if so – is it simply a matter of the relative doses? https://t.co/Bqav2pNNi7

— Bob Wachter (@Bob_Wachter) October 30, 2021

Review: How I manage a patient with MRSA bacteremia.

31 Oct, 2021 | 19:54h | UTC

How I manage a patient with MRSA bacteraemia – Clinical Microbiology and Infection

The effectiveness of the AstraZeneca vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo was 77.9% against symptomatic Covid-19, 87.6% against hospitalization, and 93.6% against death.

29 Oct, 2021 | 10:25h | UTC

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo – Nature Medicine

Commentary on Twitter (thread – click for more)

https://twitter.com/MHitchingsEpi/status/1453779176826105857

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.

29 Oct, 2021 | 10:16h | UTC

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science

Commentary from the author on Twitter (thread – click for more)

Antibodies come and go, but memory cells are forever (maybe not forever, but at least 6 months). Our latest in @ScienceMagazine: https://t.co/YHHBMrMsTA

How long does immune memory last after #mRNA vax? Is it effective vs. variants? What about “boosted” responses?

Full 🧵⬇️… pic.twitter.com/oZ5BxLuVdw

— Rishi Goel (@rishirajgoel) October 14, 2021

Systematic Review: Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors.

29 Oct, 2021 | 09:46h | UTC

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review – JAMA Oncology (free for a limited period)

Stay Updated in Your Specialty